27.32

2.57% -0.72

Agios Pharmaceuticals Inc (AGIO)

Overview News Price History Option Chain Financials Discussions Forecast

Agios Pharmaceuticals Inc stock is traded at $27.32, with a volume of 301.07K. It is down -2.57% in the last 24 hours and up +3.96% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Previous Close:

$28.04

Open:

$28.03

24h Volume:

301.07K

Relative Volume:

0.47

Market Cap:

$1.74B

Revenue:

$32.87M

Net Income/Loss:

$674.31M

P/E Ratio:

2.4049

EPS:

11.36

Net Cash Flow:

$-330.11M

1W Performance:

-9.24%

1M Performance:

+3.96%

6M Performance:

-53.74%

1Y Performance:

-17.01%

1-Day Range:

$27.27

$28.91

1-Week Range:

$27.27

$30.50

52-Week Range:

$23.41

$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name

Agios Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

617-649-8600

Address

88 SIDNEY STREET, CAMBRIDGE, MA

Employee

488

Twitter

@AgiosPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

AGIO's Discussions on Twitter

Compare AGIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AGIO Agios Pharmaceuticals Inc	27.32	1.74B	32.87M	674.31M	-330.11M	11.36
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-25	Initiated	H.C. Wainwright	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight
Nov-17-22	Upgrade	Goldman	Sell → Neutral
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-03-21	Initiated	BofA Securities	Buy
Jul-30-21	Downgrade	Goldman	Neutral → Sell
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
May-23-19	Resumed	Goldman	Neutral
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy
Apr-11-18	Reiterated	Credit Suisse	Outperform
Feb-15-18	Reiterated	Needham	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-10-17	Reiterated	Needham	Buy
Aug-08-17	Reiterated	SunTrust	Buy
Aug-02-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-17	Downgrade	Janney	Buy → Neutral
Jan-17-17	Upgrade	Oppenheimer	Perform → Outperform
Oct-24-16	Initiated	Needham	Buy
Jun-13-16	Upgrade	JP Morgan	Neutral → Overweight
May-18-16	Reiterated	SunTrust	Buy

View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

08:10 AM

Trading (AGIO) With Integrated Risk Controls - news.stocktradersdaily.com

08:10 AM

May 09, 2025

Agios to Present at the 2025 RBC Capital Markets Global Healthca - GuruFocus

May 09, 2025

Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance

May 09, 2025

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus

May 09, 2025

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times

May 09, 2025

May 08, 2025

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire

May 08, 2025

May 07, 2025

Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com

May 07, 2025

May 03, 2025

Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN

May 03, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025

Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK

May 02, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus

May 02, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times

May 02, 2025

Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan

May 02, 2025

Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus

May 02, 2025